PEG-somatropin Injection Dose-Finding, Safety, and Efficacy Study Initiated for Pediatric Turner Syndrome

The genetic disorder Turner Syndrome (TS) affects females, characterized by the absence or partial absence of an X chromosome. A primary clinical manifestation is short stature, often requiring long-term growth hormone therapy. While recombinant human growth hormone (rhGH) is an established treatment, it typically requires daily subcutaneous injections, which can impact patient adherence and quality of life. Pegylated forms of therapeutic proteins, like PEG-somatropin, are designed to extend half-life and potentially reduce injection frequency, offering a more convenient and potentially more effective treatment option by maintaining more stable therapeutic levels. This study addresses the need for optimized growth hormone delivery in TS, aiming to improve patient experience and outcomes.